Cantor Fitzgerald maintains overweight rating on NeuroPace stock

Cantor Fitzgerald reiterated its Overweight rating on NeuroPace (NPCE) with a $16 price target, despite the NAUTILUS study for idiopathic generalized epilepsy (IGE) not achieving its primary endpoint. While the study showed statistically insignificant results, subgroup data suggested potential clinical benefits for certain patients. This reaffirmation comes as NeuroPace reported strong financial performance with 22% revenue growth in 2024, reaching $79.9 million, and projects 16-21% growth for 2025, with revenue between $93 million and $97 million.

Analysis

NeuroPace Inc. (NPCE) presents a dichotomous profile for investors, characterized by strong financial momentum contrasted with a significant clinical trial setback. Cantor Fitzgerald recently reiterated its Overweight rating and a $16.00 price target, a sentiment echoed by a broader analyst consensus range of $15 to $20. This affirmation occurred despite NeuroPace's NAUTILUS study, evaluating its RNS System for idiopathic generalized epilepsy (IGE), failing to achieve its primary effectiveness endpoint—a statistically significant delay in time to a second seizure for the active stimulation group versus a sham group. However, the study did reveal clinically meaningful impact in certain patient subgroups, which the company plans to explore further with FDA submissions and peer-reviewed publications for potential indication expansion. Financially, NeuroPace demonstrates robust health, with InvestingPro data indicating 22% revenue growth and a 75% gross margin. Full-year 2024 revenue reached $79.9 million (a 22% year-over-year increase), and Q1 2025 revenue was $22.5 million (a 24% year-over-year growth). Management projects full-year 2025 revenues between $93 million and $97 million, indicating 16-21% growth. Despite these strong financials, the stock experienced a 25% drop in the past week, though it maintains a remarkable 91% return over the last year, highlighting its volatility and sensitivity to clinical news. Other analysts, such as H.C. Wainwright (Buy, $18 PT) and Leerink Partners (Outperform), also maintain positive ratings, citing revenue growth and the RNS system's safety profile, though Leerink noted concerns over the primary endpoint miss. The overall sentiment is mixed and cautious, reflecting this balance of positive fundamentals and clinical uncertainties.

Key Decisions for Investors

• Investors should carefully balance NeuroPace's strong reported revenue growth (22% in FY24, with 16-21% projected for FY25) and healthy gross margins against the clinical development risk underscored by the NAUTILUS study's failure to meet its primary endpoint for the broader IGE population.
• Closely monitor upcoming FDA submissions and peer-reviewed publications detailing the NAUTILUS study's subgroup analyses, as these outcomes are pivotal for potential future indication expansion of the RNS System and could significantly impact the company's valuation and stock performance.
• Acknowledge the stock's recent significant volatility (-25% in the past week versus +91% over the last year) and the mixed sentiment, including InvestingPro's AI analysis suggesting NPCE is not currently a top-tier 'hidden gem', when evaluating entry or exit points, despite continued analyst price targets indicating potential upside.